Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

Oncotarget. 2020 Apr 28;11(17):1573-1574. doi: 10.18632/oncotarget.27476.

Gerben R Borst^{1

2

3}, Ramya Kumareswaran^{1

2}, Hatice Yücel^{1

2

3}, Seyda Telli^{1

2}, Trevor Do^{1

2}, Trevor McKee^{1

2}, Gaetano Zafarana^{1

2}, Jos Jonkers⁴, Marcel Verheij³, Mark J O'Connor⁵, Sven Rottenberg^{4

6}, Robert G Bristow^{1

2}

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
² Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.
³ Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.
⁴ Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Molecular Biology, Amsterdam, The Netherlands.
⁵ Oncology, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.
⁶ Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.20936.].